(CONVENIENCE TRANSLATION OF THE CONSOLIDATED INTERIM FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH)

MLP SAĞLIK HİZMETLERİ A.Ş. AND ITS SUBSIDIARIES

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDED 1 JANUARY- JUNE 30, 2026

Deloitte.

DRT Bağımsız Denetim ve
Serbest Muhasebeci
Mali Müşavirlik A.Ş.
Maslak No1 Plaza
Eski Büyükdere Caddesi
Maslak Mahallesi No:1
Maslak, Sarıyer 34485
İstanbul, Türkiye

Tel: +90 (212) 366 60 00
Fax: +90 (212) 366 60 10
www.deloitte.com.tr

Mersis No :0291001097600016
Ticari Sicil No: 304099

(CONVENIENCE TRANSLATION OF THE REPORT ON REVIEW OF CONDENSED INTERIM CONSOLIDATED FINANCIAL INFORMATION ORIGINALLY ISSUED IN TURKISH)

REPORT ON REVIEW OF CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION

To the General Assembly of
MLP Sağlık Hizmetleri A.Ş.
Istanbul

Introduction

We have reviewed the accompanying condensed consolidated statement of financial position of MLP Sağlık Hizmetleri A.Ş. ("the Company") and its subsidiaries (together will be referred as "the Group") as of 30 June 2026, and the related condensed consolidated statements of profit or loss, other comprehensive income, changes in equity and cash flows and other explanatory notes for the six-month period then ended ("condensed consolidated interim financial information"). Group management is responsible for the preparation and fair presentation of this condensed consolidated interim financial information in accordance with Turkish Accounting Standards 34 "Interim Financial Reporting" ("TAS 34"). Our responsibility is to express a conclusion on this condensed consolidated interim financial information based on our review.

Scope of Review

We conducted our review in accordance with Independent Auditing Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". A review of condensed consolidated interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Independent Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Deloitte refers to a Deloitte member firm, one of its related entities, or Deloitte Touche Tohmatsu Limited ("DTTL"). Each Deloitte member firm is a separate legal entity and a member of DTTL. DTTL does not provide services to clients. Please see www.deloitte.com/about to learn more about.

© 2026. For information, contact Deloitte Türkiye, Member of Deloitte Touche Tohmatsu Limited.

Conclusion

Based on our review, nothing has come to our attention that causes us to conclude that the accompanying condensed consolidated interim financial information is not prepared, in all material respects, in accordance with TAS 34.

DRT BAĞIMSIZ DENETİM VE SERBEST MUHASEBECİ MALİ MÜŞAVİRLİK A.Ş.
Member of **DELOITTE TOUCHE TOHMATSU LIMITED**

Volkan Becerik
Partner

Istanbul, 5 August 2026

CONVENIENCE TRANSLATION INTO ENGLISH OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED 1 JANUARY – JUNE 30, 2026

INDEX **PAGE**

MLP SAĞLIK HİZMETLERİ A.Ş. AND ITS SUBSIDIARIES

CONSOLIDATED INTERIM STATEMENT OF FINANCIAL POSITION AS OF JUNE 30, 2026

(Amounts expressed in thousands Turkish Lira (“TRY”) unless otherwise stated.)

	Notes	Unaudited 30 June 2026	Audited 31 December 2025
ASSETS			
Current Assets:		**23,347,897**	**25,233,016**
Cash and cash equivalents	4	8,255,897	9,468,876
Trade receivables	3,6	11,275,572	11,571,902
- Due from related parties	*3*	*61,244*	*60,604*
- Trade receivables from third parties	*6*	*11,214,328*	*11,511,298*
Other receivables	3,7	809,379	780,729
- Due from related parties	*3*	*639,254*	*598,930*
- Other receivables from third parties	*7*	*170,125*	*181,799*
Inventories	8	1,023,451	1,307,307
Prepaid expenses	9	957,243	1,034,642
Other current assets	13	1,026,355	1,069,560
Non-current Assets:		**71,955,709**	**71,566,590**
Trade receivables	6	1,053	1,240
Other receivables	7	1,822,241	1,936,695
Property plant and equipment	10	17,809,328	17,698,387
Intangible assets		20,572,320	20,199,084
- Goodwill		*1,140,030*	*1,140,030*
- Other intangible assets	*10*	*19,432,290*	*19,059,054*
Right of use assets	11	21,598,637	21,691,794
Prepaid expenses	9	6,646,725	6,262,060
Deferred tax assets	23	3,505,405	3,777,330
TOTAL ASSETS		**95,303,606**	**96,799,606**

The accompanying notes form an integral part of these consolidated financial statements.

CONSOLIDATED INTERIM STATEMENT OF FINANCIAL POSITION AS OF JUNE 30, 2026

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

		Unaudited	**Audited**
	Notes	**30 June 2026**	**31 December 2025**
LIABILITIES AND EQUITY			
Current Liabilities:		**27,823,684**	**19,588,789**
Short term borrowings	5	1,295,566	1,302,102
Short term portion of long term borrowings	5	9,766,996	553,891
Obligations under finance leases	5	25,377	33,573
Short term lease liabilities	5	1,512,748	1,399,902
Trade payables	3,6	10,473,575	12,071,425
- Due to related parties	*3*	*78,130*	*83,222*
- Trade payables to third parties	*6*	*10,395,445*	*11,988,203*
Payables related to employee benefits	12	812,252	790,307
Other payables	3,7	430,267	620,457
- Due to related parties	*3*	*61*	*72*
- Other payables to third parties	*7*	*430,206*	*620,385*
Deferred income	9	2,625,040	1,804,709
Short term provisions		459,963	375,791
- Short term provisions for employment benefits	*12*	*255,572*	*220,956*
- Other short term provisions	*14*	*204,391*	*154,835*
Current tax liabilities	23	421,900	636,632
Non-current Liabilities:		**21,100,836**	**34,033,370**
Long term borrowings	5	2,130,238	13,272,578
Obligations under finance leases	5	29,598	39,874
Long term lease liabilities	5	6,745,645	6,948,982
Other payables		645,495	1,477,922
- Other payables to third parties	*7*	*645,495*	1,477,922
Deferred income	9	665,683	911,637
Long term provisions		417,342	359,742
- Long term provisions for employee benefits	*12*	*417,342*	*359,742*
Deferred tax liabilities	23	10,466,835	11,022,635
EQUITY:		**46,379,086**	**43,177,447**
Equity Attributable to the Owner of the Company:		**43,827,509**	**41,016,196**
Share capital	16	191,012	191,012
Adjustments for paid-in capital		4,984,683	4,984,683
Share premium		5,888,170	5,888,170
Treasury shares		(1,209,622)	(1,209,622)
Other comprehensive income or expenses that will not be reclassified		(97,190)	(143,536)
-Accumulated gain/(loss) on remeasurement of defined benefit plans		*(97,190)*	*(143,536)*
Accumulated other comprehensive income or loss to be reclassified to profit or loss		(58,646)	(80,792)
- Foreign currency translation differences arising to the translation of foreign operations		*(58,646)*	*(80,792)*
Restricted reserves	16	145,789	145,789
Accumulated income		30,830,295	24,720,603
Net profit for the period		3,153,018	6,519,889
Non-controlling interest		**2,551,577**	**2,161,251**
TOTAL LIABILITIES AND EQUITY		**95,303,606**	**96,799,606**

The accompanying notes form an integral part of these consolidated financial statements.

CONSOLIDATED INTERIM STATEMENT OF PROFIT OR LOSS FOR THE SIX-MONTH PERIOD ENDED 1 JANUARY - JUNE 30,2026

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

	Notes	Unaudited 1 January-30 June 2026	Unaudited 1 April-30 June 2026	Unaudited 1 January-30 June 2025	Unaudited 1 April-30 June 2025
PROFIT OR LOSS					
Revenue	17	34,127,444	16,735,962	32,143,591	15,682,401
Cost of sales (-)	17	(25,197,501)	(12,593,112)	(23,582,876)	(11,648,515)
GROSS PROFIT		**8,929,943**	**4,142,850**	**8,560,715**	**4,033,886**
General administration expenses (-)	18	(2,979,835)	(1,402,805)	(2,870,792)	(1,361,457)
Other income from operating activities	19	959,686	496,086	1,600,727	874,933
Other expenses from operating activities (-)	19	(1,708,927)	(728,612)	(1,375,857)	(793,259)
OPERATING PROFIT		**5,200,867**	**2,507,519**	**5,914,793**	**2,754,103**
Income from investing activities	20	17,838	10,929	373	62
Expense from investing activities (-)	20	(167,093)	(166,914)	(2,419)	514
OPERATING PROFIT BEFORE FINANCE EXPENSE		**5,051,612**	**2,351,534**	**5,912,747**	**2,754,679**
Finance expenses (-)	21	(2,954,255)	(1,486,429)	(2,714,444)	(1,378,616)
Monetary gain/(loss)	22	2,172,211	1,093,890	1,563,001	661,239
NET PROFIT BEFORE TAX		**4,269,568**	**1,958,995**	**4,761,304**	**2,037,302**
Tax expense from operations		**(726,224)**	**(408,367)**	**(1,476,453)**	**(538,862)**
Current tax expense	23	(1,025,548)	(513,024)	(861,109)	(306,290)
Deferred tax gain/loss net	23	299,324	104,657	(615,344)	(232,572)
NET PROFIT		**3,543,344**	**1,550,628**	**3,284,851**	**1,498,440**
Allocation of net profit					
Non-controlling interest		390,326	182,208	266,821	118,517
Equity holders of the parent		3,153,018	1,368,420	3,018,030	1,379,923
NET PROFIT FOR THE YEAR		**3,543,344**	**1,550,628**	**3,284,851**	**1,498,440**
Basic gain per share	**24**	**16,51**	**7,16**	**15,80**	**7,22**
OTHER COMPREHENSIVE EXPENSES		**68,492**	**(62,659)**	**(766)**	**(58,533)**
Items that will not be reclassified subsequently to profit or loss					
Remeasurement of defined benefit plans		61,795	(103,926)	69,639	(39,863)
Income tax relating to items that will not be reclassified subsequently		(15,449)	25,982	(17,409)	9,967
Items That Will Be Reclassified to Profit or Loss					
Foreign Currency Translation Difference		22,146	15,285	(52,996)	(28,637)
TOTAL COMPREHENSIVE INCOME		**3,611,836**	**1,487,969**	**3,284,085**	**1,439,907**
Total comprehensive profit distribution					
Non-controlling interest		390,326	182,208	266,821	118,517
Equity holders of the Parent		3,221,510	1,305,761	3,017,264	1,321,390

The accompanying notes form an integral part of these consolidated financial statements.

MLP SAĞLIK HİZMETLERİ A.Ş. AND ITS SUBSIDIARIES

CONSOLIDATED INTERIM STATEMENT OF CHANGES IN EQUITY
FOR THE SIX-MONTH PERIOD ENDED 1 JANUARY - JUNE 30, 2026

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

					Other comprehensive income or expenses that will not be reclassified	Other comprehensive income and (losses) to be reclassified to profit or loss		Accumulated gain				
	Share capital	**Positive distinction from share capital adjusment**	**Share premium**	**Treasury shares**	**Accumulated gain/(loss) on remeasurement of defined benefit plans**	**Foreign currency translation differences**	**Restricted reserves**	**Accumulated deficit**	**Net profit for the period**	**Equity Attributabe to the Owner of the Company**	**Non-controlling interest**	**Total equity**
Balance as at January 1, 2025	**191,012**	**4,984,683**	**5,888,170**	**(1,209,622)**	**(131,289)**	**182**	**145,789**	**16,976,878**	**8,030,346**	**34,876,149**	**1,397,500**	**36,273,649**
Other comprehensive income for the period, net of tax	-	-	-	-	52,230	(52,996)	-	-	-	(766)	-	(766)
Net profit for the period	-	-	-	-	-	-	-	-	3,018,030	3,018,030	266,821	3,284,851
Total comprehensive gain/(loss) for the period	**-**	**-**	**-**	**-**	**52,230**	**(52,996)**	**-**	**-**	**3,018,030**	**3,017,264**	**266,821**	**3,284,085**
Transfers	-	-	-	-	-	-	-	8,030,346	(8,030,346)	-	-	-
Dividend distribution	-	-	-	-	-	-	-	(275,823)	-	(275,823)	-	(275,823)
Balance as at June 30, 2025	**191,012**	**4,984,683**	**5,888,170**	**(1,209,622)**	**(79,059)**	**(52,814)**	**145,789**	**24,731,401**	**3,018,030**	**37,617,590**	**1,664,321**	**39,281,911**
			-									
Balance as at January 1, 2026	**191,012**	**4,984,683**	**5,888,170**	**(1,209,622)**	**(143,536)**	**(80,792)**	**145,789**	**24,720,603**	**6,519,889**	**41,016,196**	**2,161,251**	**43,177,447**
Other comprehensive income for the period, net of tax	-	-	-	-	46,346	22,146	-	-	-	68,492	-	68,492
Net profit for the period	-	-	-	-	-	-	-	-	3,153,018	3,153,018	390,326	3,543,344
Total comprehensive gain/(loss) for the period	**-**	**-**	**-**	**-**	**46,346**	**22,146**	**-**	**-**	**3,153,018**	**3,221,510**	**390,326**	**3,611,836**
Transfers	-	-	-	-	-	-	-	6,519,889	(6,519,889)	-	-	-
Dividend distribution	-	-	-	-	-	-	-	(410,197)	-	(410,197)	-	(410,197)
Balance as at June 30, 2026	**191,012**	**4,984,683**	**5,888,170**	**(1,209,622)**	**(97,190)**	**(58,646)**	**145,789**	**30,830,295**	**3,153,018**	**43,827,509**	**2,551,577**	**46,379,086**

The accompanying notes form an integral part of these consolidated financial statements.

NOTES TO THE CONSOLIDATED CASH FLOWS
AS OF JUNE 30, 2026

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

	Notes	Unaudıted 1 January- 30 June 2026	Unaudıted 1 January- 30 June 2025
CASH FLOWS FROM OPERATING ACTIVITIES		**7,567,112**	**5,051,649**
Profit / (loss) for the period		3,543,344	3,284,851
Profit / (loss) continuing operations		**6,156,362**	**3,964,985**
- Adjustments related to depreciation and amortization expenses	10-11	4,004,419	2,259,740
- Adjustments related to impairment (reversal		1,673	(7,743)
Adjustments related to impairment (reversal) of receivables	*6*	*1,673*	*(7,743)*
- Adjustments related to provisions		181,819	131,810
Adjustments related to (reversal) of provision for employment benefits		*60,450*	*52,225*
Adjustments related to lawsuit (reversal) of provision for lawsuit		*121,369*	*79,585*
- Adjustments related to interest (income) expense		1,645,693	1,020,193
Adjustments related to interest income		*(1,318,404)*	*(679,276)*
Adjustments related to interest expense	*21*	*2,964,097*	*1,699,469*
- Adjustments related to tax (gain) loss	23	726,224	1,476,453
- Other adjustments related to non-cash items		(61,689)	(93,554)
- Adjustments related to (gain) loss on sale of fixed assets		149,255	(2,046)
Adjustments related to (gain) loss on sale of tangible assets		*149,255*	*(2,046)*
Monetary gain/ loss	*22*	(491,032)	(819,868)
Changes in working		**(852,733)**	**(1,203,035)**
- Adjustments related to increase in trade receivables		(1,096,071)	(2,621,249)
- Adjustments related to increase in inventories		283,856	61,717
- Adjustments related to increase in trade payables		261,881	1,325,456
- Adjustments related to inrcrease in other payables from operations		(681,225)	(645,276)
- Adjustments related to other (increase) decrease in working capital		378,826	676,317
Adjustments related to inrcrease in other payables from other asset		*378,826*	*676,317*
Cash generated from operations		**8,846,973**	**6,046,801**
- Payments related with provision for employee benefits		(128,623)	(78,734)
- Tax paid	23	(1,091,864)	(910,739)
Payments for other provisions		(59,589)	(5,921)
- Other cash inflows (outflows)		215	242
CASH FLOWS FROM INVESTING ACTIVITIES		**(3,108,201)**	**(4,959,954)**
-Proceeds from sales of property, plant, equipment and intangible assets	10	679,138	2,213
Proceeds from sales of property, plant, equipment		679,138	2,213
-Payment for purchase of property, plant and equipment, intangible assets		**(3,869,134)**	**(3,062,324)**
Payment for purchase of property, plant and equipment	*10*	*(3,346,881)*	*(2,936,244)*
Payment for purchase of intangible assets	*10*	*(522,253)*	*(126,080)*
Cash Advances and Loans Given	9	81,795	(1,899,843)
CASH FLOWS FROM FINANCING ACTIVITIES		**(4,266,149)**	**7,965,553**
- Cash inflows from borrowings		**636,431**	**14,379,932**
Cash inflows from loans		636,431	5,132,297
Cash inflows from debt securities issued		-	9,247,635
- Bank borrowings paid		**(348,933)**	**(3,291,398)**
Cash used for repayment of borrowings		(348,933)	(649,217)
Cash used for repayment of bonds		-	(2,642,181)
- Repayment of lease liabilities		(1,627,141)	(1,467,551)
- Repayment of obligations under finance leases		(18,472)	(18,938)
- Interest paid		(3,816,241)	(2,039,946)
- Interest received		1,318,404	679,276
- Dividend paid		(410,197)	(275,822)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS BEFORE THE EFFECT OF FOREIGN CURRENCY TRANSLATION DIFFERENCES		**192,762**	**8,057,248**
EFFECT OF FOREIGN CURRENCY TRANSLATION DIFFERENCES ON CASH AND CASH EQUIVALENTS		22,208	(52,996)
NET INCREASE / (DECREASE) IN CASH AND CASH EQUIVALENTS		**214,970**	**8,004,252**
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD	4	9,468,876	4,204,267
INFLATION EFFECT ON CASH AND CASH EQUIVALENTS		(1,427,949)	(600,833)
CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD	**4**	**8,255,897**	**11,607,686**

The accompanying notes form an integral part of these consolidated financial statements.

NOTE 1 - ORGANIZATION AND OPERATIONS OF THE GROUP

MLP Sağlık Hizmetleri A.Ş. ("MLP Sağlık") has started its healthcare services operations in 1993, with the opening of Sultangazi Medical Center within the structure of Yükseliş Sağlık Hizmetleri Gıda Tekstil San. Ltd. Şti. in which Muharrem Usta is the majority shareholder. Following this, in 1995, it continues its operations, with the opening of Fatih Hospital under the legal entity of Saray Sağlık Hizmet Ticaret ve Sanayi A.Ş. in which Muharrem Usta was the majority shareholder. In 2005, with the establishment of MLP Sağlık, Fatih and Sultangazi Hospitals were merged under the legal entity of MLP Sağlık.

As of June 30, 2026, MLP is the holding company of 18 subsidiaries (December 31, 2025: 17) (collectively referred as the "Group"), each operating in the healthcare sector in Turkey.

The Company's head office is located in Otakçılar Caddesi No 78 34050, Eyüp, İstanbul.

The Group has an agreement with the Social Security Institution of Turkey (the "SSI") which includes service commitment in all branches disclosed in the Operations Approval Document. SSI is a state enterprise which pays the healthcare expenditures of the citizens of Turkey who are members of the social security system based on the law numbered 5510, and manages social security premiums and short and long term insurance expenses. According to the agreement, the Group is obliged to provide the healthcare services and to issue invoices to the SSI and patients in line with the Communiqué of Health Services published by the SSI. This transaction is performed through Medula, a web based software system, by assessing the right of the patient and obtaining provisions. As a result of the assessment the expenses relating to patients with no SSI, coverage is not charged to SSI. The healthcare expenses provided to the patients are invoiced based on the terms of the Communiqué of Health Services. In this Communiqué SSI determined a price list based on the treatments provided. Invoices are issued based on the price list announced by the Communiqué. SSI has the right not to pay the invoice or make a deduction if the treatments provided are not in compliance with the terms.

The Company is registered to the Capital Markets Board ("CMB") and its shares have been quoted on the Borsa İstanbul A.Ş. ("BİAŞ or "Borsa" or "BİST") since February 13, 2018. In accordance with the resolution numbered 21/655 on July 23, 2010 of CMB; according to the records of Central Registry Agency (CRA); shares representing 41,73% as of June 30 2026, of MLP Sağlık are accepted as "in circulation". As of July 1, 2026, this ratio is 41,73% (Note 16).

The number of employees of the Group as at 30 June 2026 is 14,635 (31 December 2025: 12,940).

Approval of financial statements

Board of Directors has approved the financial statements and delegated authority for publishing it on August 5, 2026.

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 1 - ORGANIZATION AND OPERATIONS OF THE GROUP (Continued)

As of June 30, 2026, the subsidiaries of the Company are:

Name	Location and base of operation
Temar Tokat Manyetik Rezonans Sağlık Hizmetleri ve Turizm A.Ş. ("Tokat Hastanesi")	Tokat
Samsun Medikal Grup Özel Sağlık Hizmetleri A.Ş. ("Samsun Hastanesi")	Samsun-İstanbul
Kuzey Medikal Pazarlama İnşaat Taşımacılık San. ve Tic. Ltd. Şti. ("Kuzey")	Ankara
Artımed Medikal Sanayi ve Ticaret A.Ş. ("Artımed")	Ankara
MS Sağlık Hizmetleri Ticaret A.Ş. ("MS Sağlık")	Ankara
Mediplaza Sağlık Hizmetleri Ticaret A.Ş. ("Mediplaza")	Gebze – İzmit
21. Yüzyıl Anadolu Vakfı ("21.Yüzyıl Anadolu Vakfı")	İstanbul
Sotte Sağlık Temizlik Yemek Medikal Turizm Insaat San. ve Tic. A.Ş. ("Sotte Sağlık Temizlik Yemek")	İstanbul - Ankara
BTR Sağlık Hizmetleri A.Ş. ("BTR Sağlık")	İstanbul
İstanbul Meditime Sağlık Hizmetleri Ticaret Ltd. Şti. ("Meditime Sağlık")	İstanbul
MLP Gaziantep Sağlık Hizmetleri Anonim Şirketi ("MLP Gaziantep Sağlık")	Gaziantep
Kuzey Doğu Sağlık Hizmetleri ve Tic. A.Ş. ("Kuzey Doğu")	İstanbul
Livist Sağlık Hizmetleri Ltd.	Kıbrıs
MLP İzmir Sağlık Hizmetleri A.Ş..	İstanbul - İzmir
MLP Ataşehir Sağlık Hizmetleri A.Ş.	İstanbul
MLPARK Facilities Management Services L.L.C	Dubai
Bileşim Turizm Sanayi Ticaret A.Ş.	İstanbul
İstanbul Gelişim Özel Sağlık Hizmetleri Tic. A.Ş.	İstanbul

NOTE 2 - BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS

2.1 Basis of Presentation

Statement of Compliance with TFRS

The condensed consolidated financial statements of the Group have been prepared in accordance with the Turkish Financial Reporting Standards, ("TFRS") and interpretations as adopted in line with international standards by the Public Oversight Accounting and Auditing Standards Authority of Turkey ("POA") in line with the communiqué numbered II-14.1 "Communiqué on the Principles of Financial Reporting In Capital Markets" ("the Communiqué") announced by the Capital Markets Board of Turkey ("CMB") on June 13, 2013 which is published on Official Gazette numbered 28676.

The Company prepared its condensed interim financial statements for the period ended 30 June 2026 in accordance with ("IAS") 34 "Interim Financial Reporting". The condensed interim financial statements and its accompanying notes are presented in compliance with the format recommended by CMB including its mandatory information. In compliance with the IAS 34, entities have preference in presenting their interim financial statements whether full set or condensed. In this framework, the Company preferred to present its interim financial statements in condensed.

Interim condensed financial statements of the Group do not include all the information and disclosures required in the annual financial statements, therefore should be read in conjunction with the Company's annual financial statements as of 31 December 2025.

Currency Used

Each entity within the Group presents its individual financial statements in the currency of the primary economic environment in which it operates (the functional currency). The financial position and performance results of each entity are expressed in Turkish Lira ("TRY"), which is the functional and presentation currency of the Group for the consolidated financial statements. As of 30 June 2026, the functional currency of the Kosovo branch of Samsun Medikal Grup Özel Sağlık Hizmetleri A.Ş. is the Euro ("EUR"), while that of the company operating in Dubai is the United Arab Emirates Dirham ("AED"). For the Group entities that prepare their financial statements in a functional currency other than TRY, income statements have been translated into TRY using the average exchange rates for the respective year. The assets and liabilities of these entities have been translated into TRY at the closing exchange rates at the end of the reporting period. Exchange differences arising from the translation of the opening net assets and from the difference between average and closing exchange rates have been recognized under the foreign currency translation differences account within equity.

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 2 - BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Continued)

2.1 Basis of Presentation (Continued)

Comparative Information and Restatement of Prior Period Financial Statements

In order to identify financial position and performance trends, the Group's condensed consolidated financial statements are prepared on a comparative basis with the prior period. Where necessary, comparative figures are reclassified to conform to the presentation of the current period's condensed consolidated financial statements, and material differences are disclosed accordingly.

Basis of Consolidation

The details of the Company ant its subsidiaries as at June 30, 2026 and December 31, 2025 are as follows:

Subsidiaries	Place of incorporation and operation	30 June 2026	31 December 2025	Principal activity
Tokat Hastanesi	Tokat	58,84%	58,84%	Hospital services
Samsun Hastanesi (2)	Samsun	80,00%	80,00%	Hospital services
MS Sağlık	Ankara	100,00%	100,00%	Hospital services
Mediplaza	Gebze-İzmit	75,00%	75,00%	Hospital services
BTR Sağlık Hizmetleri	İstanbul	100,00%	100,00%	Hospital services
Meditime Sağlık	İstanbul	100,00%	100,00%	Hospital services
MLP Gaziantep Sağlık	Gaziantep	100,00%	100,00%	Hospital services
Sotte Sağlık Temizlik Yemek	İstanbul - Ankara	100,00%	100,00%	Hospital services
Livist Sağlık Hizmetleri Ltd.	Kıbrıs	99,99%	99,99%	Hospital services
MLP İzmir	İstanbul – İzmir	65,00%	65,00%	Hospital services
Kuzey	Ankara	100,00%	100,00%	Ancillary services
Artımed	Ankara	100,00%	100,00%	Ancillary services
21. Yüzyıl Anadolu Vakfı (1)	İstanbul	100,00%	100,00%	Ancillary services
Kuzey Doğu	İstanbul	100,00%	100,00%	Ancillary services
MLP Ataşehir	İstanbul	100,00%	100,00%	Ancillary services
Bileşim Turizm Sanayi Ticaret A.Ş.	İstanbul	100,00%	100,00%	Hospital services
İstanbul Geli.Öz.Sağlık.Hizmetleri(4)	İstanbul	100,00%	-	Ancillary services
MLPARK Fac. Man. Ser. L.L.C (3)	Dubai	100,00%	100,00%	Ancillary services

(1) Represents voting power held. In 2011, the Group with the help of its real person shareholders decided to establish a medical university. Based on current legislation, foundations have to be owned by real persons rather than companies and since MLP Sağlık could not be the shareholder of an association, Muharrem Usta, one of the shareholders in the company, was assigned as the chairman of the board of the foundation. The purpose of the foundation is to establish a medical university in order to align one of the hospitals of the Group to that university. Although, MLP Sağlık has no shareholder interest in the foundation, the financial statements of the foundation are consolidated to the financial statements in accordance with TFRS 10 as the Company achieved the control by having power and the ability to use its power on the future benefit and cost of the foundation. In addition, the Company has rights to the financial and operating policies of the university from its involvement with the investee.

(2) As of October 2024, a hospital operating in Kosovo was opened under Samsun Hospital. The functional currency of the related branch is Euro.

(3) As of September 2025, a legal entity operating in Dubai has been established. The functional currency of the relevant company is the United Arab Emirates Dinar.

(4) There is no active hospital operation.

NOTE 2 - BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Continued)

2.1 Basis of Presentation (Continued)

The consolidated financial statements incorporate the financial statements of the Company and entities controlled by the Company and its subsidiaries. Control is achieved when the Company:

- Has power over the investee,
- Is exposed, or has rights, to variable returns from its involvement with the investee and
- Has the ability to use its power to affect its returns.

The Company reassesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control listed above.

In cases where the Company has no majority voting rights on the company/asset invested, it still has the control power over that company/asset if the Company alone has sufficient voting rights to manage the investment operations of that company/asset. The Company considers all events and requirements including the items listed below to evaluate if its voting power is sufficient to get control power in an investment:

- The comparison of the Company's voting right and other shareholders' voting rights;
- Potential voting rights of the Company and other shareholders;
- Rights emerging from other agreements upon contracts;
- Other events and requirements showing the potential power of the Company in managing operation decisions (including the voting held on prior period general assemblies).

Consolidation of a subsidiary begins when the Company obtains control over the subsidiary and ceases when the Company loses control of the subsidiary. Specifically, income and expenses of a subsidiary acquired or disposed of during the year are included in the consolidated statement of profit or loss and other comprehensive income from the date the Company gains control until the date when the Company ceases to control the subsidiary.

Profit or loss and each component of other comprehensive income are attributed to the owners of the Company and to the non-controlling interests. Total comprehensive income of subsidiaries is attributed to the owners of the Company and to the non-controlling interests even if this results in the non-controlling interests having a deficit balance.

Where necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies in line with those used by other members of the Group.

All intra-group assets and liabilities, equities, income and expenses and cash flows resulting from of Group companies' transactions are eliminated on consolidation.

<u>Changes in the Group's ownership interests in existing subsidiaries</u>

Changes in the Group's ownership interests in subsidiaries that do not result in the Group losing control over the subsidiaries are accounted for as equity transactions. The carrying amounts of the Group's interests and the non-controlling interests are adjusted to reflect the changes in their relative interests in the subsidiaries. Any difference between the amount by which the non-controlling interests are adjusted and the fair value of the consideration paid or received is recognized directly in equity and attributed to owners of the Company.

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 2 - BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Continued)

2.1 Basis of Presentation (Continued)

When the Group loses control of a subsidiary, a gain or loss is recognised in profit or loss and is calculated as the difference between (i) the aggregate of the fair value of the consideration received and the fair value of any retained interest and (ii) the previous carrying amount of the assets (including goodwill), and liabilities of the subsidiary and any non-controlling interests. All amounts previously recognised in other comprehensive income in relation to that subsidiary are accounted for as if the Group had directly disposed of the related assets or liabilities of the subsidiary (i.e. reclassified to profit or loss or transferred to another category of equity as specified/permitted by applicable TFRS). The fair value of the remaining investment at the date when control over the subsidiary is lost is regarded either as the fair value at initial recognition in accordance with TFRS 9 Financial Instruments, or, where applicable, as the cost of the investment at initial recognition in an associate or a jointly controlled entity.

Restatement of financial statements during periods of high inflation

In accordance with the CMB's decision dated 28 December 2023 and numbered 81/1820, issuers and capital market institutions subject to financial reporting regulations applying Turkish Accounting/Financial Reporting Standards are required to apply inflation accounting by applying the provisions of TAS 29 to their annual financial statements for the accounting periods ending on 31 December 2023.

POA made an announcement on 23 November 2023 regarding the scope and application of TAS 29. It stated that the financial statements of the entities applying Turkish Financial Reporting Standards for the annual reporting period ending on or after 31 December 2023 should be presented in accordance with the related accounting principles in TAS 29, adjusted for the effects of inflation.

In this framework, while preparing the consolidated financial statements dated 30 June 2026, 31 December 2025 and 30 June 2026 inflation adjustment has been made in accordance with TAS 29.

The financial statements and related figures for previous periods have been restated for changes in the general purchasing power of the functional currency and, consequently, the financial statements and related figures for previous periods are expressed in terms of the measuring unit current at the end of the reporting period in accordance with TAS 29 Financial Reporting in Hyperinflationary Economies.

TAS 29 applies to the financial statements, including the consolidated financial statements, of each entity whose functional currency is the currency of a hyperinflationary economy. If an economy is subject to hyperinflation, TAS 29 requires an entity whose functional currency is the currency of a hyperinflationary economy to present its financial statements in terms of the measuring unit current at the end of the reporting period.

As at the reporting date, entities operating in Turkey are required to apply TAS 29 "Financial Reporting in Hyperinflationary Economies" for the reporting periods ending on or after 31 December 2023, as the cumulative change in the general purchasing power of the last three years based on the Consumer Price Index ("CPI") is more than 100%.

The table below shows the inflation rates for the relevant years calculated by taking into account the Consumer Price Indices published by the Turkish Statistical Institute (TURKSTAT):

Date	**Index**	**Adjusment Coefficient**
30.06.2026	4.137,93	1,00000
31.12.2025	3.513,87	1,17758
30.06.2025	3,132.17	1,32109

NOTE 2 - BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Continued)

2.1 Basis of Presentation (Continued)

Restatement of financial statements during periods of high inflation (Continued)

The main lines of TAS 29 indexation transactions are as follows:

• As of the balance sheet date, all items other than those stated in terms of current purchasing power are restated by using the relevant price index coefficients. Prior year amounts are also restated in the same way.

• Monetary assets and liabilities are expressed in terms of the purchasing power at the balance sheet date and are therefore not subject to restatement. Monetary items are cash and items to be received or paid in cash.

2.2 Changes in Accounting Policies

Significant changes made in accounting policies are applied retrospectively and prior year financial statements are restated. In current period, the Group has no changes in its accounting policies other than the change disclosed in Note 2.1.

2.3 Changes in the Accounting Estimates and Errors

If changes in accounting estimates are for only one period, changes are applied on the current year but if the changes in accounting estimates are for the following periods, changes are applied both on the current and the following years prospectively. In the current period, the Group has no changes in the accounting estimates and errors.

2.4 Significant Accounting Estimates and Decisions

Preparation of consolidated financial statements requires management to make estimations and assumptions which may affect the reported amounts of assets and liabilities as of the statement of financial position date, the disclosure of contingent assets and liabilities and the reported amounts of income and expenses during the financial period. The accounting assessments, estimates and assumptions are reviewed considering past experiences, other factors and reasonable expectations about future events under current conditions. Although the estimations and assumptions are based on the best estimates of the management's existing incidents and operations, they may differ from the actual results.

2.5 New and Amended Turkish Financial Reporting Standards

a) Amendments that are mandatorily effective from 2026

Amendments to TFRS 9 and TFRS 7 *Classification and Measurement of Financial Instruments*
Amendments to TFRS 9 and TFRS 7 *Power Purchase Arrangements*
Annual Improvements *Annual Improvements to TFRSs – Volume 11*

Amendments to TFRS 9 and TFRS 7 *Classification and Measurement of Financial Instruments*
The amendments address matters identified during the post-implementation review of the classification and measurement requirements of TFRS 9 *Financial Instruments*. Amendments are effective from annual reporting periods beginning on or after 1 January 2026.

Amendments to TFRS 9 and TFRS 7 *Power Purchase Arrangements*

The amendments aim at enabling entities to include information in their financial statements that in the IASB's view more faithfully represents contracts referencing nature-dependent electricity. Amendments are effective from annual reporting periods beginning on or after 1 January 2026.

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 2 - BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Continued)

2.5 New and Amended Turkish Financial Reporting Standards (Continued)

Annual Improvements to TFRSs – Volume 11
The pronouncement comprises the following amendments:

- TFRS 1: Hedge accounting by a first-time adopter
- TFRS 7: Gain or loss on derecognition
- TFRS 7: Disclosure of deferred difference between fair value and transaction price
- TFRS 7: Introduction and credit risk disclosures
- TFRS 9: Lessee derecognition of lease liabilities
- TFRS 9: Transaction price
- TFRS 10: Determination of a 'de facto agent'
- TAS 7: Cost method

Amendments are effective from annual reporting periods beginning on or after 1 January 2026.

The aforementioned standard, amendments and improvements do not have any significant effect on the Group's financial position and performance.

b) <u>New and revised TFRSs in issue but not yet effective</u>

The Group has not yet adopted the following standards and amendments and interpretations to the existing standards:

TFRS 17	*Insurance Contracts*
Amendments to TFRS 17	*Initial Application of TFRS 17 and TFRS 9 — Comparative Information*
TFRS 18	*Presentation and Disclosures in Financial Statements*
TFRS 19	*Subsidiaries without Public Accountability: Disclosures*
Amendments to TFRS 19	*Subsidiaries without Public Accountability: Disclosures*
Amendments to TAS 21	*Translation to a Hyperinflationary Presentation Currency*
Amendments to IAS 28	*Amendments to the Fair Value Option for Investments in Associates and Joint*

TFRS 17 *Insurance Contracts*

TFRS 17 requires insurance liabilities to be measured at a current fulfillment value and provides a more uniform measurement and presentation approach for all insurance contracts. These requirements are designed to achieve the goal of a consistent, principle-based accounting for insurance contracts. TFRS 17 has been deferred for insurance, reinsurance and pension companies for a further year and will replace TFRS 4 *Insurance Contracts* on 1 January 2027.

NOTE 2 - BASIS OF PRESENTATION OF CONSOLIDATED FINANCIAL STATEMENTS (Continued)

2.5 New and Amended Turkish Financial Reporting Standards (Continued)

Amendments to TFRS 17 *Insurance Contracts* and *Initial Application of TFRS 17 and TFRS 9 – Comparative Information*

Amendments have been made in TFRS 17 in order to reduce the implementation costs, to explain the results and to facilitate the initial application.

The amendment permits entities that first apply TFRS 17 and TFRS 9 at the same time to present comparative information about a financial asset as if the classification and measurement requirements of TFRS 9 had been applied to that financial asset before. Amendments are effective with the first application of TFRS 17.

TFRS 18 *Presentation and Disclosures in Financial Statements*

TFRS 18 includes requirements for all entities applying TFRS for the presentation and disclosure of information in financial statements. This standard is effective from annual reporting periods beginning on or after 1 January 2027.

TFRS 19 *Subsidiaries without Public Accountability: Disclosures*

TFRS 19 specifies the disclosure requirements an eligible subsidiary is permitted to apply instead of the disclosure requirements in other IFRS Accounting Standards. This standard is effective from annual reporting periods beginning on or after 1 January 2027.

Amendments to TFRS 19 *Subsidiaries without Public Accountability: Disclosures*

The amendments cover new or amended Turkish Financial Reporting Standards that were not considered when TFRS 19 was first issued. Amendments are effective from annual reporting periods beginning on or after 1 January 2027.

Amendments to TAS 21 *Translation to a Hyperinflationary Presentation Currency*

The amendments clarify how companies should translate financial statements from a non-hyperinflationary currency into a hyperinflationary one. Annual reporting periods beginning on or after 1 January 2027.

Amendments to TAS 28 *Amendments to the Fair Value Option for Investments in Associates and Joint Ventures*

The amendments provide clarity about which entities are eligible to measure investments using the fair value option in TAS 28. Annual reporting periods beginning on or after 1 January 2027.

The Group evaluates the effects of these standards, amendments and improvements on the consolidated financial statements.

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 3 - RELATED PARTY DISCLOSURES

Transactions between the Company and its subsidiaries, which are related parties of the Company, have been eliminated on consolidation and are not disclosed in this note.

The details of short-term receivables and payables as of 30 June 2026 are as follows:

	30 June 2026			
	Receivables		Payables	
	Short-term		Short-term	
Shareholders	**Trade**	**Non-trade**	**Trade**	**Non-trade**
Muharrem Usta (*)	-	525,279	-	50
Adem Elbaşı	-	24,917	-	-
Hikmet Çavuş	-	88,920	-	-
Other companies controlled by the shareholders				
A ve A Sağlık A.Ş. (2)	7,481	-	22,204	-
Cotyora Med. Öz. S. Hz. İnş. Tr. Loj. Ltd. Şti. (4)	-	-	13,817	-
Fom Grup Mimarlık İnşaat ve Tic. A.Ş. (1)	201	-	14,775	-
Pozitif Medikal Sistemler San. ve Tic. Ltd. Şti.	2	-	509	-
Samsunpark Özel Sağlık Tıbbı Malz. İnş. Tur. Tem. Tic. A.Ş. (3)	-	-	26,635	-
MLP Healthcare UK (5)	52,806	-	-	-
Saray Eczanesi	-	-	30	-
Tokat Emar Sağlık Hiz. Ltd. Şti.	-	-	154	-
Özel Gebze Sentez Sağlık Hizmetleri Ve Tic. A.Ş.	-	-	-	7
Miniso Mağazacılık A.Ş.	634	-	-	-
Other	120	138	6	4
	61,244	**639,254**	**78,130**	**61**

(*) Non-trade receivables from Muharrem Usta is short term due date and interest charge from the current value of internal debt ratio of Group.

(1) Fom Grup Mimarlık İnşaat ve Tic. A.Ş. provides the Group's hospitals with turnkey fixed asset and leasehold improvement procurement services, as well as construction and inspection services for hospitals under development.

(2) A ve A Özel Sağ. Hiz. ve Cih. Teks. San. Tic. Ltd. Şti. provides cleaning materials for the hospitals.

(3) Samsunpark Özel Sağlık Tıbbı Malz. İnş. Tur. Tem. Tic. A.Ş. provides cleaning, catering and laundry services for the Group.

(4) Cotyora Med. Özel Sağ. Taah. Hz. İnş. Tr. Loj. Ltd. Şti. provides cleaning and catering services for the Group.

(5) MLP Healthcare UK operates in the healthcare sector and provides consultancy services in this field.

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 3 - RELATED PARTY DISCLOSURES (Continued)

	31 December 2025			
	Receivables		Payables	
	Short-term		Short-term	
Shareholders	**Trade**	**Non-trade**	**Trade**	**Non-trade**
Muharrem Usta (*)	-	487,952	-	59
Adem Elbaşı	-	23,064	-	-
Hikmet Çavuş	-	87,750	-	-
Other companies controlled by the shareholders				
A ve A Sağlık A.Ş. (2)	6,184	-	19,470	-
Fom Grup Mimarlık İnşaat ve Tic. A.Ş. (1)	1,151	-	27,874	-
Özel Gebze Sentez Sağlık Hizmetleri Ve Tic. A.Ş.	-	-	-	8
MLP Healthcare Uk	53,202	-	-	-
Cotyora Med. Özel Sağ. Taah. Hz. İnş. Tr. Loj. Ltd. Şti. (4)	-	-	13,578	-
Pozitif Medikal Sistemler San. ve Tic. Ltd. Şti.	2	-	599	-
Saray Eczanesi	-	-	110	-
Samsunpark Özel Sağlık Tıbbı Malz. İnş. Tur. Tem. Tic. A.Ş. (3)	-	-	21,397	-
Tokat Emar Sağlık Hiz. Ltd. Şti.	-	-	194	-
Diğer	65	164	-	5
	60,604	**598,930**	**83,222**	**72**

(*) Non-trade receivables from Muharrem Usta is short term due date and interest charge from the current value of internal debt ratio of Group.
(1) Fom Grup Mimarlık İnşaat ve Tic. A.Ş. provides the Group's hospitals with turnkey fixed asset and leasehold improvement procurement services, as well as construction and inspection services for hospitals under development.
(2) A ve A Özel Sağ. Hiz. ve Cih. Teks. San. Tic. Ltd. Şti. provides cleaning materials for the hospitals.
(3) Samsunpark Özel Sağlık Tıbbı Malz. İnş. Tur. Tem. Tic. A.Ş. provides cleaning, catering and laundry services for the Group.
(4) Cotyora Med. Özel Sağ. Taah. Hz. İnş. Tr. Loj. Ltd. Şti. provides cleaning and catering services for the Group.
(5) MLP Healthcare UK operates in the healthcare sector and provides consultancy services in this field.

Advances given to related parties and prepaid expenses	30 June 2026	31 December 2025
Fom Grup Mimarlık İnşaat ve Tic. A.Ş. (1)	13,850	16,310
Sanport Gayrimenkul Geliştirme İnş.Ve Tic.A.Ş	279	328
	14,129	**16,638**

Fixed asset advances given to related parties	30 June 2026	31 December 2025
Fom Grup Mimarlık İnşaat ve Tic. A.Ş. (1)	2,162,654	2,162,654
Sanport Gayrimenkul Geliştirme İnş. Ve Tic. A.Ş.	452.757	-
	2.615.411	**2,162,654**

(1) Fom Grup Mimarlık İnşaat ve Tic. A.Ş. provides turn key project management services for the furniture & fixture and leasehold improvements of the hospitals and audit of ongoing construction of the Group hospitals.

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 3 - RELATED PARTY DISCLOSURES (Continued)

	30 June 2026		31 December 2025	
Lease liabilities from related parties	**Short-term**	**Long-term**	**Short-term**	**Long-term**
Sanport Gayrimenkul Geliştirme İnş. ve Tic. A.Ş	278,392	941,909	170,916	888,423
Fom Grup Mimarlık İnşaat Ve Tic. A.Ş.	45,233	273,703	71,379	53,852
Atakum Özel Sağlik Hizmetleri İnş.Turizm ve San. Tic. A.Ş.	22,227	556,998	23,090	669,819
Özel Gebze Sentez Sağlık Hizmetleri ve Tic. A.Ş.	32,369	-	53,189	-
Tokat Medikal Grup Sağlık Turizm İnş. San. Tic. A.Ş.	13,377	84,756	15,926	6,156
Bilmed Eğitim ve Sağlık Hizmetleri A.Ş.	40	13,248	39	15,626
Usfam Sağlık Bilişim Tic. A.Ş.	39	13,247	38	15,625
	391,677	**1,883,861**	**334,577**	**1,649,501**

Purchases from related parties	1 January-30 June 2026	1 January-30 June 2025
A ve A Sağlık A.Ş. (1)	58,460	82,999
Fom Grup Mimarlık İnşaat ve Tic. A.Ş. (2)	291,890	42,634
	350,350	**125,633**

(1) Cleaning material purchases
(2) Hospital rent expenses

Operating expenses (including purchase of services)	1 January-30 June 2026	1 January-30 June 2025
Sanport Gayrimenkul Geliştirme İnş. ve Tic.A.Ş (1)(7)	357,894	370,236
Atakum Özel Sağlik Hiz. İnş. Turizm ve San. Tic. A.Ş. (1)(7)	85,913	94,523
Samsunpark Özel Sağ. Tıbbi Malz. İnş. Tur. Tem. Tic. A.Ş. (4)	82,108	80,000
Cotyora Med. Özel Sağ. Taah. Hz. İnş. Tr. Loj. Ltd. Şti. (4)	46,555	48,742
Tokat Medikal Grup Sağlık Turizm İnş. San. Tic. A.Ş. (1)(7)	37,472	20,407
Özel Gebze Sentez Sağlık Hizmetleri ve Tic. A.Ş. (1)(7)	35,908	42.062
Atk Sağlık Hizmetleri Ve Danışmanlık A.Ş. (3)	23,970	20,672
Tokat Emar Sağlık Hiz. Ltd. Şti. (2) (5)	6,761	9,787
Livart Tüp Bebek Özel Sağlık Hizm. A.Ş. (2)	3,178	36,743
Özdenler Sağ. Hiz. Dan. Turz. Gıd. San. Tic. Ltd. Şti. (2)	2,231	2,735
Usfam Sağlık Bilişim Tic. A.Ş.(7)	2,716	-
Saray Eczanesi (6)	546	501
	685,252	**726.408**

(1) Hospital rent expenses
(2) Doctor expenses
(3) Consultancy service
(4) Cleaning, catering and laundry services
(5) Medical equipment rent expenses
(6) Drug purchase expenses
(7) Assessed within the scope of TFRS 16 and represents the lease payments made for the related period.

Sales to related parties	1 January-30 June 2026	1 January-30 June 2025
Sanport Gayrimenkul Geliştirme İnş. ve Tic. A.Ş.	1,168,260	-
Adem Elbaşı	4,564	4,445
Hikmet Çavuş	3,336	1,102
Samsunpark Özel Sağlık Tıbbi Malz. İnş. Turizm. Tem. Tic. A.Ş.	1,691	1,929
A ve A Sağlık A.Ş. (1)	1,347	860
Cotyora Med.Özel Sağ.Taah. Hz. İnş. Tr. Loj. Ltd. Şti.	1,344	1,416
Miniso Mağazacılık A.Ş.	1,061	933
Tokat Medikal Grup Sağlık Turizm İnş. San. Tic. A.Ş.	186	198
Fom Grup Mimarlık İnşaat ve Tic. A.Ş.	178	1,414
MLP Health Uk	84	4,172
	1,182,051	**16,469**

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 3 - RELATED PARTY DISCLOSURES (Continued)

Interest income from related parties	1 January-30 June 2026	1 January-30 June 2025
Muharrem Usta	96,251	97,554
	96,251	**97,554**

Benefits provided to key management personnel:

The Company's key management personnel consist of general managers, deputy general managers, chief physicians, and central senior management. Benefits provided to key management personnel include salaries, bonuses, health insurance, and transportation, among others. The benefits provided to key management personnel during the period are as follows:

	1 January-30 June 2026	1 April-30 June 2026	1 January-30 June 2025	1 April-30 June 2025
Salaries and Similar Benefits Paid to Key Management Personnel	163,273	80,316	166,369	76,039
	163,273	**80,316**	**166,369**	**76,039**

NOTE 4 - CASH AND CASH EQUIVALENTS

	30 June 2026	31 December 2025
Cash on hand	19,342	49,771
Cash at banks	8,162,970	9,353,273
- Demand deposit	*360,971*	*930,611*
- Time deposit	*7,801,999*	*8,422,662*
Other cash equivalents (*)	73,585	65,832
	8,255,897	**9,468,876**

(*) Other cash equivalents consist of credit card receivables from banks.

As of 30 June 2026, the interest rates of the Group's time deposits in TRY, is respectively 36%-41% and their terms are less than 3 months. (31 December 2025: 28%-40%)

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 5 - FINANCIAL INSTRUMENTS

Bank Loans and Bonds

	30 June 2026	31 December 2025
Short Term Bank Borrowings	1,286,998	1,281,910
Short Term Bonds Issued	8,568	20,192
Current Portion of Long Term Borrowings	9,766,996	553,891
- Current portion of long-term bank loans	*2,766,996*	*553,891*
-Current portion of issued bonds	*7,000,000*	-
	11,062,562	**1,855,993**
Long Term Bank Borrowings	2,130,238	5,029,482
Long Term Bonds Issued	-	8,243,096
	2,130,238	**13,272,578**
Total Borrowings	**13,192,800**	**15,128,571**

The Group issued bonds with a maturity of 24 months totaling TRY 5,000,000, sold to qualified investors as of 30 June 2026. The principal repayment will be made at maturity on 28 June 2027, and the interest rate is TLRef + 1.75.

The Group also issued green bonds with a maturity of 24 months totaling TRY 2,000,000, sold to qualified investors as of 30 June 2026. The principal repayment will be made at maturity on 28 June 2027, and the interest rate is TLRef + 1.75.

The reconciliation of the liabilities arising from financing activities as of 1 January- 30 June 2026 and 1 January- 31 December 2025 are as follows:

	1 January 2026	Financing cash flows	Foreign exchange effect (Note21)	Other (*)	Effect of Inflation	30 June 2026
Bank Loans	15,128,571	156,486	201,028	-	(2,293,285)	13,192,800
Finance lease obligations	73,447	(10,146)	2,750	-	(11,076)	54,975
Lease obligations	8,348,884	(1,627,141)	15,447	2,780,251	(1,259,048)	8,258,393
	23,550,902	**(1,480,801)**	**219,225**	**2,780,251**	**(3,563,409)**	**21,506,168**

	1 January 2025	Financing cash flows	Foreign exchange effect (Note 21)	Other (*)	Effect of Inflation	31 December 2025
Bank Loans	5,228,400	10,188,764	1,050,307	-	(1,338,900)	15,128,571
Finance lease obligations	75,685	6,505	9,120	-	(17,863)	73,447
Lease obligations	7,009,797	(2,724,969)	49,376	5,673,976	(1,659,296)	8,348,884
	12,313,882	**7,470,300**	**1,108,803**	**5,673,976**	**(3,016,059)**	**23,550,902**

(*) Some of the lease obligations within the scope of TFRS 16 are due to the re-measurement of the reduced lease obligations and interest expenses due to the change in the lease payments realized within the period.

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 5 - FINANCIAL INSTRUMENTS (Continued)

As of June 30, 2026 and December 31, 2025 the repayment schedule of the total borrowings as follows:

30 June 2026

Currency Type	Weighted Average Effective Interest Rate	Current	Non-Current	Total
TL	28,8%	1,099,254	-	1,099,254
TRLibor	TRLibor+2,45 - TLRef+1,75	8,000,000	-	8,000,000
EUR	EurLibor +0,89; +3,40; +3,60	1,963,308	2,130,238	4,093,546
		11,062,562	**2,130,238**	**13,192,800**

31 December 2025

Currency Type	Weighted Average Effective Interest Rate	Current	Non-Current	Total
TL	30,41%	1,441,451	-	1,441,451
TL	TLRef+2,45-+1,75	-	9,420,678	9,420,678
EUR	EurLibor +0,89; +3,40; +3,60; +4,90	414,542	3,851,900	4,266,442
		1,855,993	**13,272,578**	**15,128,571**

As of June 30, 2026, there are no blocked cash accounts related to the group's loans (December 31, 2025: None).

As at June 30, 2026 and December 31, 2025 the repayment schedule of the borrowings in TRY are as follows:

	30 June 2026	31 December 2025
Interest expense accruals	176,525	139,352
To be paid within 1 year (*)	10,886,038	1,716,641
To be paid between 1-2 years	504,032	11,617,608
To be paid between 2-3 years	231,804	351,414
To be paid between 3-4 years	278,379	162,035
To be paid between 4-5 years	260,278	162,035
To be paid between 5-6 years	855,744	979,486
	13,192,800	**15,128,571**

(*) Of the loans payable within one year, TRY 7,000,000 corresponds to revolving credits, while the remaining amount represents the current portion of long-term loans.

Covenants:

The Group entered into a loan agreement with DZ Bank AG on 25 September 2024 and commenced utilizing the loan as of January 2025. The said loan agreement contains a financial covenant: In the event that the Net Debt to EBITDA ratio exceeds 2.5 during the term of the agreement (2025-2035), the procedures specified in the contract will proceed upon mutual agreement. The Net Debt to EBITDA ratio is tested at each year-end, commencing from 31 December 2025. As of 31 December 2025, the Group complied with the ratio stipulated in the aforementioned covenant.

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 5 - FINANCIAL INSTRUMENTS (Continued)

Lease Obligations

The Group has the following finance lease obligations which arose mainly due to lease of medical machinery and equipment:

	Minimum lease payments		Present value of minimum lease payments	
	30 June 2026	**31 December 2025**	**30 June 2026**	**31 December 2025**
Within one year	37,832	49,060	25,377	33,573
In second to sixth years inclusive	25,679	36,737	29,598	39,874
	63,511	**85,797**	**54,975**	**73,447**
Less: Future finance charges	(8,536)	(12,350)	-	-
Present value of finance lease obligations	**54,975**	**73,447**	**54,975**	**73,447**
Less: Amounts due to settlement within twelve months (shown under cuurent laibilities)	-	-	25,377	33,573
Present value of finance lease obligations	**54,975**	**73,447**	**29,598**	**39,874**

NOTE 6 - TRADE RECEIVABLES AND PAYABLES

Trade Receivables

Current trade receivables	**30 June 2026**	**31 December 2025**
Trade receivables	8,125,632	8,705,677
Notes receivables	917	1,514
Trade receivables from related parties (Note 3)	61,244	60,604
Income accruals from continuing treatments	3,102,098	2,977,434
Other trade income accruals	186,002	60,889
Allowance for doubtful receivables (-)	(200,321)	(234,216)
	11,275,572	**11,571,902**

Non-current trade receivables	**30 June 2026**	**31 December 2025**
Income accruals	1,053	1,240
	1,053	**1,240**

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 6 - TRADE RECEIVABLES AND PAYABLES (Continued)

Allowance for doubtful receivables for the trade receivables is determined depending on past experiences of irrecoverable amounts.

As of June 30, 2026, trade receivables of an initial value of TRY 200,321 (December 31, 2025: TRY 234,216) were fully impaired and fully provided for. No collaterals are received in relation to these trade receivables.

Movement of allowance for doubtful receivables	1 January-30 June 2026	1 January-31 December 2025
Opening balance	234,216	226,914
Charge for the period (Note 18)	1,673	62,897
Collections	(216)	(672)
Inflation effect	(35,352)	(54,923)
Ending balance	**200,321**	**234,216**

Trade Payables

Current trade payables	30 June 2026	31 December 2025
Trade payables	6,365,334	7,699,843
Trade payables due to related parties (Note 3)	78,130	83,222
Other expense accruals	3,915,792	4,219,073
Other trade payables	114,319	69,287
	10,473,575	**12,071,425**

NOTE 7 - OTHER RECEIVABLES AND PAYABLES

Other Receivables

Other current receivables	30 June 2026	31 December 2025
Receivables from tax office	107,446	107,488
Non-trading receivables due from related parties (Note 3)	639,254	598,930
Deposits given	2,149	1,606
Other miscellaneous receivables	60,530	72,705
	809,379	**780,729**

Other non-current receivables	30 June 2026	31 December 2025
Deposits and guarantees given	1.822.241	1,936,695
	1.822.241	**1,936,695**

Other Payables

Other current payables	30 June 2026	31 December 2025
Other taxes and funds payable	203,382	331,964
Payables relating to business combinations (*)	194,782	238,872
Non-trading payables due to related parties (Note 3)	61	72
Other miscellaneous payables	32,042	49,549
	430,267	**620,457**

Other non-current payables	30 June 2026	31 December 2025
Payables relating to business combinations (*)	645,495	1,477,922
	645,495	**1,477,922**

(*) The Group has committed to deferred payment schedules extending into future periods in connection with certain business combination agreements executed in 2014, 2020, 2022, 2024 and 2025. The related liability represents the present value of the consideration payable in future periods. For agreements denominated in Turkish Lira, the weighted average interest rate is 35% and the average maturity is 9 years (2024: 35% and 9 years). For agreements denominated in U.S. Dollars, the weighted average interest rate is 9% and the average maturity is 2 years (2024: 9% and 2 years).

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 8 – INVENTORIES

	30 June 2026	31 December 2025
Medical consumables inventory	756,837	1,027,709
Pharmaceutical inventory	249,056	275,860
Other inventories	17,558	3,738
	1,023,451	**1,307,307**

As of 30 June 2026, there are no pledges/mortgages on inventories (31 December 2025: None).

As of 30 June 2026, there is no impairment on inventories (31 December 2025: None).

NOTE 9 - PREPAID EXPENSES AND DEFERRED INCOME

Prepaid Expenses

Short term prepaid expenses	30 June 2026	31 December 2025
Advances given	583,698	560,394
Advances Given to Related Parties (Note 3)	14,129	16,638
Prepaid insurance expenses	102,495	229,982
Prepaid rent expenses	13,546	102,426
Prepaid sponsorship expenses	8,559	3,209
Other	234,816	121,993
	957,243	**1,034,642**

Long term prepaid expenses	30 June 2026	31 December 2025
Fixed asset advances given (*)	3,988,671	4,071,001
Advances to Related Parties for Fixed Assets (Note 3)	2.615.411	2,162,654
Other	42,643	28,405
	6.646.725	**6,262,060**

(*) Advances consist of mainly the turnkey hospital projects regarding new and renovated hospitals and the order advances given for the construction services for the hospitals under construction.

Deferred Income

Short term accrued income	30 June 2026	31 December 2025
Advances received (*)	2,125,843	1,304,973
Deferred revenue	499,197	499,736
	2,625,040	**1,804,709**

(*) Advances are received from mainly local and medical tourism related patients with regards to cost of their treatments. After treatments are completed, realized remunerations are netted with advances.

Long term accrued income	30 June 2026	31 December 2025
Deferred revenue	665,683	911,637
	665,683	**911,637**

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 10 - PROPERTY, EQUIPMENT AND OTHER INTANGIBLE ASSETS

	Land	Buildings	Machinery and equipments	Vehicles	Furniture and fixtures	Leased assets	Leasehold improvements	Construction in progress	Total
Cost									
Opening balance as of 1 January 2026	3,074,539	21,509	16,385,305	48,250	6,059,908	7,835,817	16,814,298	2,273,936	52,513,562
Additions	-	-	347,992	-	269,369	67,236	634,176	2,028,108	3,346,881
Disposals	(1,373,775)	(8,078)	(59,809)	(1,544)	(21,700)	-	(3,950)	(33,421)	(1,502,277)
Currency Translation Differences	-	-	16,928	-	-	-	-	-	16,928
Transfers	-	-	500,352	-	-	-	-	(500,352)	-
Closing balance as of 30 June 2026	**1,700,764**	**13,431**	**17,190,768**	**46,706**	**6,307,577**	**7,903,053**	**17,444,524**	**3,768,271**	**54,375,094**
Accumulated depreciations									
Opening balance as of 1 January 2026	-	(8,231)	(11,626,001)	(35,338)	(4,800,755)	(7,835,817)	(10,509,033)	-	(34,815,175)
Charge for the period (*)	-	(203)	(602,960)	(1,532)	(313,910)	(4,202)	(906,310)	-	(1,829,117)
Disposals	-	8,078	59,809	1,544	12,353	-	2,041	-	83,825
Currency Translation Differences	-	-	(5,299)	-	-	-	-	-	(5,299)
Closing balance as of 30 June 2026	**-**	**(356)**	**(12,174,451)**	**(35,326)**	**(5,102,312)**	**(7,840,019)**	**(11,413,302)**	**-**	**(36,565,766)**
Carrying value as of 30 June 2026	**1,700,764**	**13,075**	**5,016,317**	**11,380**	**1,205,265**	**63,034**	**6,031,222**	**3,768,271**	**17,809,328**

(*) Depreciation and amortization expense of TRY 1,879,904 (January 1 - June 30, 2025: TRY 1,324,184) has been charged in 'cost of service', TRY 98,501 (January 1-June 30, 2025: TRY 100,469) has been included in general administrative expenses.

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 10 - PROPERTY, EQUIPMENT AND OTHER INTANGIBLE ASSETS (Continued)

	Land	Buildings	Machinery and equipments	Vehicles	Furniture and fixtures	Leased assets	Leasehold improvements	Construction in progress	Total
Cost									
Opening balance as of 1 January 2025	1,655,192	21,509	13,905,781	39,309	5,308,037	7,799,051	14,100,436	849,755	43,679,070
Additions	-	-	359,394	-	208,665	-	658,796	1,709,389	2,936,244
Currency translation differences	-	-	33,680	-	-	-	-	-	33,680
Disposals	-	-	(69)	-	(2,201)	-	(22,595)	-	(24,865)
Closing balance as of 30 June 2025	**1,655,192**	**21,509**	**14,298,786**	**39,309**	**5,514,501**	**7,799,051**	**14,736,637**	**2,559,144**	**46,624,129**
Accumulated depreciations									
Opening balance as of 1 January 2025	-	(7,826)	(10,572,921)	(33,409)	(4,304,616)	(7,760,619)	(9,035,581)	-	(31,714,972)
Charge for the period	-	(203)	(485,099)	(695)	(190,164)	(38,432)	(643,188)	-	(1,357,781)
Currency translation differences	-	-	(2,513)	-	-	-	-	-	(2,513)
Disposals	-	-	69	-	1,359	-	20,147	-	21,575
Closing balance as of 30 June 2025	**-**	**(8,029)**	**(11,060,464)**	**(34,104)**	**(4,493,421)**	**(7,799,051)**	**(9,658,622)**	**-**	**(33,053,691)**
Carrying value as of 30 June 2025	**1,655,192**	**13,480**	**3,238,322**	**5,205**	**1,021,080**	**-**	**5,078,015**	**2,559,144**	**13,570,438**

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 10 - PROPERTY, EQUIPMENT AND OTHER INTANGIBLE ASSETS (Continued)

	Licenses	Rights	Total
Cost			
Opening balance as of 1 January 2026	17,999,557	3,418,486	21,418,043
Additions	-	522,253	522,253
Currency translation differences	-	275	275
Disposals	-	(406)	(406)
Closing balance as of 30 June 2026	**17,999,557**	**3,940,608**	**21,940,165**
Accumulated amortization			
Opening balance as of 1 January 2026	-	(2,358,989)	(2,358,989)
Charge for the period	-	(149,288)	(149,288)
Currency translation differences	-	(4)	(4)
Disposals	-	406	406
Closing balance as of 30 June 2026	**-**	**(2,507,875)**	**(2,507,875)**
Carrying value as of 30 June 2026	**17,999,557**	**1,432,733**	**19,432,290**

	Licenses	Rights	Total
Cost			
Opening balance as of 1 January 2025	12,335,490	2,879,728	15,215,218
Additions	-	126,080	126,080
Currency translation differences	-	3,265	3,265
Closing balance as of 30 June 2025	**12,335,490**	**3,009,073**	**15,344,563**
Accumulated amortization			
Opening balance as of 1 January 2025	-	(2,180,713)	(2,180,713)
Charge for the period	-	(66,872)	(66,872)
Currency translation differences	-	(143)	(143)
Closing balance as of 30 June 2025	**-**	**(2,247,728)**	**(2,247,728)**
Carrying value as of 30 June 2025	**12,335,490**	**761,345**	**13,096,835**

NOTE 11- RIGHT OF USED ASSETS

	Hospital Buildings	Total
Cost		
1 January 2026	22,308,014	22,308,014
Additions	1,316,637	1,316,637
Charge for the period	(2,026,014)	(2,026,014)
30 June 2026	**21,598,637**	**21,598,637**

(*) For the period ended June 30, 2026, right of use assets depreciation expenses of TRY 2,016,559 has been charged to 'cost of service' (1 January – 30 June 2025: TRY 818,671), TRY 9,455 to 'general administrative and marketing expenses (1 January – 30 June 2025: TRY 16,416).

	Hospital Buildings	Total
Cost		
1 January 2025	19,381,343	19,381,343
Additions	2,794,730	2,794,730
Charge for the period	(835,087)	(835,087)
30 June 2025	**21,340,986**	**21,340,986**

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 12- PAYABLES FOR EMPLOYEE BENEFITS

	30 June 2026	31 December 2025
Fees payable to doctors and other personnel	568,484	545,661
Social security premiums payable	243,768	244,646
	812,252	**790,307**

	30 June 2026	31 December 2025
Unused vacation provision	255,572	220,956
	255,572	**220,956**

	30 June 2026	31 December 2025
Unused vacation provision	200,567	167,290
Retirement pay provision	216,775	192,452
	417,342	**359,742**

NOTE 13 - OTHER ASSETS AND LIABILITIES

	30 June 2026	31 December 2025
VAT carried forward	982,362	1,008,130
Other miscellaneous current assets	43,993	61,430
	1,026,355	**1,069,560**

NOTE 14 - PROVISIONS

Other short term provisions	30 June 2026	31 December 2025
Litigation provisions	137,056	81,057
Social Security discounts provisions	67,335	73,778
	204,391	**154,835**

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 15 - COMMITMENTS

30 June 2026	Total TRY Equivalent	TRY	USD	EUR
A.CPM given on behalf of its own legal entity				
- Collateral	2,602,483	2,427,391	116	3,196
- Pledge	-	-	-	-
- Mortgage	-	-	-	-
B. CPM given on behalf of the subsidiaries included in full consolidation	-	-	-	-
- Collateral	443,812	443,812	-	-
- Pledge	-	-	-	-
- Mortgage	-	-	-	-
C. CPM given for execution of ordinary commercial activities to collect third parties debt	-	-	-	-
- Collateral	-	-	-	-
- Pledge	-	-	-	-
- Mortgage	-	-	-	-
D. Total amount of other CPM given	-	-	-	-
i. Total Amount of CPM on behalf of the main partner	-	-	-	-
- Collateral	-	-	-	-
- Pledge	-	-	-	-
- Mortgage	-	-	-	-
ii. Total amount of CPM given on behalf of other Company companies that do not cover B and C	-	-	-	-
- Collateral	-	-	-	-
- Pledge	-	-	-	-
- Mortgage	-	-	-	-
iii. Total amount of CPM on behalf of third parties that do not cover C	-	-	-	-
- Collateral	-	-	-	-
- Pledge	-	-	-	-
- Mortgage	-	-	-	-
Total	**3,046,295**	**2,871,203**	**116**	**3,196**

The Group has given guarantees amounting to TRY 350,290 related to the loans in Note 5 for the companies under full consolidation.

The guarantees given include letters of guarantee obtained from banks to be provided to suppliers.

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 15 - COMMITMENTS (Continued)

31 December 2025	Total TRY Equivalent	TRY	ABD Doları	Avro
A.CPM given on behalf of its own legal entity				
- Collateral	2,660,700	2,453,398	156	3,357
- Pledge	-	-	-	-
- Mortgage	-	-	-	-
B. CPM given on behalf of the subsidiaries included in full consolidation	-	-	-	-
- Collateral	418,843	418,843	-	-
- Pledge	-	-	-	-
- Mortgage	-	-	-	-
C. CPM given for execution of ordinary commercial activities to collect third parties debt	-	-	-	-
- Collateral	-	-	-	-
- Pledge	-	-	-	-
- Mortgage	-	-	-	-
D. Total amount of other CPM given	-	-	-	-
i. Total Amount of CPM on behalf of the main partner	-	-	-	-
- Collateral	-	-	-	-
- Pledge	-	-	-	-
- Mortgage	-	-	-	-
ii. Total amount of CPM given on behalf of other Company companies that do not cover B and C	-	-	-	-
- Collateral	-	-	-	-
- Pledge	-	-	-	-
- Mortgage	-	-	-	-
iii. Total amount of CPM on behalf of third parties that do not cover C	-	-	-	-
- Collateral	-	-	-	-
- Pledge	-	-	-	-
- Mortgage	-	-	-	-
Total	**3,079,543**	**2,872,241**	**156**	**3,357**

The Group has given guarantees amounting to TRY 323,159 related to the loans in Note 5 for the companies under full consolidation.

The guarantees given include letters of guarantee obtained from banks to be provided to suppliers.

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 16 - SHARE CAPITAL/OTHER RESERVES

Shareholders	%	30 June 2026	%	31 December 2025
Sancak Yatırım İç ve Dış Ticaret A.Ş.	%16,72	31,943	%16,72	31,943
Lightyear Healthcare B.V.	%14,04	26,823	%14,04	26,823
F.O.M.Grup Mimarlık İnşaat ve Ticaret A.Ş.	%11,24	21,470	%11,24	21,470
Muharrem Usta	%9,78	18,678	%9,78	18,678
Adem Elbaşı	%2,62	5,003	%2,62	5,003
İzzet Usta	%1,30	2,490	%1,30	2,490
Saliha Usta	%0,98	1,868	%0,98	1,868
Nurgül Dürüstkan Elbaşı	%0,98	1,868	%0,98	1,868
Publicly Traded (*)	%42,34	80,869	%42,34	80,869
	%100	**191,012**	**%100**	**191,012**
Capital adjustment differences		4,984,683		4,984,683
Share capital		**5,175,695**		**5,175,695**

As of June 30, 2026 the total number of ordinary shares is 191,012 thousand shares (2024: 191,012 thousand shares) with a par value of TRY 1 per share (2025: TRY 1 per share).

The share capital is divided into 191,012 thousand shares (December 31, 2025: 191,012 thousand shares), with 88,229 thousand A type shares and 102,783 thousand B type shares.

In accordance with the Capital Markets Board's (the "CMB") Resolution No: 21/655 issued on July 23, 2010, it is regarded that 41,73% of the shares are in circulaton in accordance with CSD as of June 30, 2026 (Note 1). Shares in circulation rate is 41,73% as of July 1, 2026.

On February 7, 2018, the Group launched initial public offering ("IPO") of 72,834 thousand B type bearer shares corresponding to 35.01% of total shares. From the initial public offering, TRY600,000 was generated to the Group. After the IPO related expenses amounting to TRY12,259 were deducted from proceeds, out of TRY587,741, share capital increase was made with the amount of TRY31,579 and the remaning amount was used in the share premium increase by TRY556,162.

The related amount became TRY 5,888,170 after applying inflation accounting.

	30 June 2026	31 December 2025
Share premiums	5,888,170	5,888,170
	5,888,170	**5,888,170**

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 16- SHARE CAPITAL/OTHER RESERVES (Continued)

Legal reserves

The legal reserves consist of first and second legal reserves, appropriated in accordance with the Turkish Commercial Code. The first legal reserve is appropriated out of historical statutory profits at the rate of 5% per annum, until the total reserve reaches 20% of the historical paid-in share capital. The second legal reserve is appropriated after the first legal reserve and dividends, at the rate of 10% per annum of all cash dividend distributions.

	30 June 2026	31 December 2025
Legal reserves	9,690	9,690
Restricted reserves appropriated from profit	136,099	136,099
	145,789	**145,789**

NOTE 17 - REVENUE AND COST OF SERVICES

Revenue	1 January-30 June 2026	1 April-30 June 2026	1 January-30 June 2025	1 April-30 June 2025
Hospital services (*)	34,127,444	16,735,962	32,143,591	15,682,401
	34,127,444	**16,735,962**	**32,143,591**	**15,682,401**

(*) Hospital services includes foreign medical revenue and other income.

Cost of services	1 January-30 June 2026	1 April-30 June 2026	1 January-30 June 2025	1 April-30 June 2025
Material consumption	(3,659,373)	(1,769,474)	(3,884,807)	(1,899,582)
Doctor expenses	(9,332,664)	(4,840,367)	(8,654,876)	(4,335,018)
Personnel expenses	(5,388,426)	(2,514,896)	(5,807,521)	(2,803,019)
Depreciation and amortization expenses (Note 10,11)	(3,896,463)	(2,015,085)	(2,142,855)	(1,097,612)
Services rendered by third parties	(661,029)	(313,228)	(672,946)	(311,648)
Lease Expenses	(618,663)	(320,242)	(746,548)	(332,489)
Other (*)	(1,640,883)	(819,820)	(1,673,323)	(869,147)
	(25,197,501)	**(12,593,112)**	**(23,582,876)**	**(11,648,515)**

(*) Other expenses mainly comprise expenses incurred for rent, electricity, water and natural gas.

NOTE 18 - OPERATING EXPENSES

General administrative expenses	1 January-30 June 2026	1 April-30 June 2026	1 January-30 June 2025	1 April-30 June 2025
Personnel expenses	(1.637.304)	(727,398)	(1,616,048)	(750,246)
Sponsorship and advertising expenses (*)	(653.037)	(329,388)	(637,334)	(312,588)
Depreciation and amortization expenses (Note 10,11)	(107.956)	(51,591)	(116,885)	(56,852)
Outsourcing expenses	(143.304)	(82,225)	(151,828)	(68,831)
Lease Expenses	(77.185)	(29,173)	(53,451)	(29,767)
Taxes and duties	(18.982)	(8,430)	(10,427)	(4,827)
Bad debt allowance (Note 6)	(1.673)	(900)	(7,743)	(1,676)
Representation and entertainment expenses	(3.184)	(1,918)	(2,988)	(1,590)
Maintenance expenses	(9.429)	(4,245)	(8,771)	(3,641)
Service expenses	(3.257)	(1,741)	(2,840)	(1,409)
Communication expenses	(20.620)	(10,605)	(18,790)	(9,163)
Lawsuit provision (Note 14)	(72.607)	(5,730)	(15,458)	(5,809)
Other	(231.297)	(149,461)	(228,229)	(115,058)
	(2.979.835)	**(1,402,805)**	**(2,870,792)**	**(1,361,457)**

(*) Sponsorship and advertising expenses includes marketing expenses related to the income of domestic and foreign medical tourism.

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 19 - OTHER INCOME AND EXPENSES FROM OPERATING ACTIVITIES

Other income from operating activities	1 January-30 June 2026	1 April-30 June 2026	1 January-30 June 2025	1 April-30 June 2025
Foreign exchange gains from operations	647,195	343,820	1,394,353	752,274
Trade payables discount	39,307	20,677	58,717	59,555
Other income	273,184	131,589	147,657	63,104
	959,686	**496,086**	**1,600,727**	**874,933**

Other expenses from operating activities	1 January-30 June 2026	1 April-30 June 2026	1 January-30 June 2025	1 April-30 June 2025
Foreign exchange losses from operations	(495,434)	(222,556)	(735,653)	(478,233)
SSI return expenses	(130,406)	(57,674)	(57,232)	(30,279)
Non-operational hospital expenses	(521,120)	(136,449)	(150,277)	(31,169)
Trade receivables discount	(82,248)	(13,066)	-	-
Other expenses	(479,719)	(298,867)	(432,695)	(253,578)
	(1,708,927)	**(728,612)**	**(1,375,857)**	**(793,259)**

NOTE 20 - INCOME AND EXPENSES FROM INVESTING ACTIVITIES

Income from investment activities	1 January-30 June 2026	1 April-30 June 2026	1 January-30 June 2025	1 April-30 June 2025
Gain on sale of fixed assets	17,838	10,929	373	62
	17,838	**10,929**	**373**	**62**

Expenses from investment activities	1 January-30 June 2026	1 April-30 June 2026	1 January-30 June 2025	1 April-30 June 2025
Loss on sale of fixed assets	(167,093)	(166,914)	(2,419)	514
	(167,093)	**(166,914)**	**(2,419)**	**514**

NOTE 21 - FINANCE EXPENSES

	1 January-30 June 2026	1 April-30 June 2026	1 January-30 June 2025	1 April-30 June 2025
Interest expenses from bonds issued	(1,548,692)	(772,763)	(300,358)	(114,205)
Interest expenses from lease liabilities	(1,089,337)	(514,745)	(1,022,631)	(491,813)
Bank commissions	(510,858)	(249,402)	(469,229)	(247,131)
Interest expenses from bank borrowings	(502,203)	(249,867)	(596,661)	(256,078)
Other interest expenses	(399,302)	(189,598)	(328,263)	(181,347)
Interest expenses from financial lease obligations	(3,042)	(1,345)	(4,958)	(2,301)
Total interest expenses	**(4,053,434)**	**(1,977,720)**	**(2,722,100)**	**(1,292,875)**
Net foreign exchange loss from lease liabilities (Note 5)	(15,447)	(13,204)	(31,344)	(18,655)
Net foreign exchange loss (Note 5)	(203,778)	(155,641)	(640,276)	(417,991)
Total financial expenses	**(4,272,659)**	**(2,146,565)**	**(3,393,720)**	**(1,729,521)**
Interest income	1,318,404	660,136	679,276	350,905
Finance expenses, net	**(2,954,255)**	**(1,486,429)**	**(2,714,444)**	**(1,378,616)**

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 22 – DISCLOSURES ON NET MONETARY POSITION GAINS (LOSSES)

Non-Monetary Items	30 June 2026	30 June 2025
Statement of Financial Position Items		
Inventories	(12,614)	(38,699)
Prepaid Expenses (Current)	(4,094)	(7,790)
Property, Plant and Equipment	1,016,494	853,226
Intangible Assets	1,718,146	740,083
Right-of-Use Assets	1,157,633	1,082,337
Prepaid Expenses (Non-Current)	416,689	306,397
Deferred Tax Liability	186,775	520,403
Deferred Income	(54,596)	(24,691)
Paid-in Capital	(33,921)	(42,075)
Share Premium	(107,731)	(122,510)
Treasury Shares	98,766	133,631
Accumulated Other Comprehensive Income (Loss) Not to be Reclassified to Profit or Loss	66,950	63,025
Restricted Reserves Appropriated from Profit	2,203	(2,733)
Retained Earnings (Accumulated Losses)	(3,021,941)	(2,590,196)
Statement of Profit or Loss Items		
Revenue	(1,714,454)	(1,540,463)
Cost of Sales	2,003,905	1,898,888
General Administrative Expenses	300,869	191,466
Other Income from Operating Activities	(50,227)	(94,493)
Other Expenses from Operating Activities (-)	93,866	56,779
Income from Investing Activities	(1,926)	137
Finance Costs	126,070	133,188
Income Tax Expense	(14,651)	47,091
NET MONETARY POSITION GAINS (LOSSES)	**2,172,211**	**1,563,001**

NOTE 23 - TAXES ON INCOME (DEFERRED TAX ASSET AND LIABILITIES INCLUDED)

Short term payables due to current tax	30 June 2026	31 December 2025
Current period tax liabilities	421,900	636,632
	421,900	**636,632**

Current tax liabilities	30 June 2026	31 December 2025
Current corporate tax provision	1,025,548	2,320,626
Less: Prepaid taxes and funds	(603,648)	(1,683,994)
	421,900	**636,632**

Tax (expense)/income	1 January -30 June 2026	1 January -30 June 2025
Current tax expense	(1,025,548)	(861,109)
Deffered tax income/(expense)	299,324	(615,344)
	(726,224)	**(1,476,453)**

Corporate Tax

The Group is subject to Turkish corporate taxes in force. The necessary provisions are allocated in the consolidated financial statements for the estimated liabilities based on the Group's results for the year. Turkish tax legislation does not permit a parent company and its subsidiary to file a consolidated tax return. Therefore, provisions for taxes, as reflected in the consolidated financial statements, have been calculated on a separate-entity basis.

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 23 - TAXES ON INCOME (DEFERRED TAX ASSET AND LIABILITIES INCLUDED) (Continued)

Corporate tax is applied on taxable corporate income, which is calculated from the statutory accounting profit by adding non-deductible expenses, and by deducting dividends received from resident companies, other exempt income and investment incentives utilized.

In Turkey, provisional tax is calculated and accrued on a quarterly basis. The provisional tax rate to be calculated on corporate earnings during the taxation phase of 2026 corporate earnings as of temporary tax periods is 25% (2025: 25%). Losses can be carried forward for a maximum of 5 years, to be deducted from the taxable profits that will arise in future years. However, the losses incurred cannot be deducted retrospectively from the profits of previous years.

Deferred Tax

The Group recognizes deferred tax assets and liabilities based upon temporary differences arising between its financial statements as reported for TFRS purposes and its statutory tax financial statements. These differences usually result in the recognition of revenue and expenses in different reporting periods for TFRS and tax purposes and they are given below. As of 30 June 2026, tax rate used in the calculation of deferred tax assets and liabilities was 25% over temporary timing differences (30 June 2025: 25%) for the part that will create tax effect in 2026, 25% for the part that will generate tax in 2024 and beyond.(30 June 2025 25%)

In Turkey, the companies cannot declare a consolidated tax return, therefore subsidiaries that have deferred tax assets position were not netted off against subsidiaries that have deferred tax liabilities position and disclosed separately.

Investment Incentive Certificate

The Group has various investment incentive certificates that were signed by the Turkish Ministry of Economy and approved by General Directorate of Incentive Implementation and Foreign Capital. With those incentives, the Group is eligible for a corporate tax deduction rate ranging between 40%-80% for an unlimited time, which amounts to a total deferred tax asset of TRY 1,168,048 (December 31, 2024: TRY 1,311,615). Respective deferred tax asset was calculated to be 15%-40% of total investment contribution with regards to the respective investment incentive certificates.

As of June 30 2026, the Group has tax loss amounting to TRY 148,532 (December 31, 2024: TRY 164,560). TRY 37,133 (December 31, 2024: TRY 41,140) deferred tax assets have been recorded concerning this loss.

Deffered tax assets/ (liabilities)	**30 June 2026**	**31 December 2025**
Tax losses carried forward	37,133	41,140
Depreciation differences of tangible and intangible assets	(5,418,232)	(5,983,075)
Tax advantage from investment incentive	1,168,048	1,311,615
Right of use asset	(3,335,061)	(3,335,727)
Other	586,682	720,742
	(6,961,430)	**(7,245,305)**
Deferred tax asset	3,505,405	3,777,330
Deferred tax liability	(10,466,835)	(11,022,635)
	(6,961,430)	**(7,245,305)**

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 23 - TAXES ON INCOME (DEFERRED TAX ASSET AND LIABILITIES INCLUDED) (Continued)

Movement of deferred tax (assets)/liabilities for the period ended June 30, 2026 and June 30, 2025 are as follows:

Movement of deferred tax liabilities	**1 January-30 June 2026**	**1 January-30 June 2025**
Opening balance as of January 1	(7,245,305)	(4,698,378)
Charged to profit or loss	299,324	(615,344)
Charged to equity	(15,449)	(17,409)
	(6,961,430)	**(5,331,131)**

The reconciliation of the current tax expense and net income for the period is as follows:

Reconcilation of tax provision:	**1 January-30 June 2026**	**1 January-30 June 2025**
Loss before tax	**4,269,568**	**4,761,304**
Tax at the domestic income tax rate of 25% (2024: 25%)	(1,067,392)	(1,190,326)
Tax effects of		
- Expenses that are not deductible in	(220,695)	(193,622)
- Effect of tax advantage from investment incentive	32,803	49,896
- Reduced corporate tax effect	238,212	137,832
- Other	(267,869)	(280,233)
-Revalued amount (*)	558,717	-
Income tax income recognised in profit or loss	**(726,224)**	**(1,476,453)**

(*) It results from the revaluation gains on fixed assets under the conditions set forth in Transitional Article 32 and Repeated Article 298/ç of the Tax Procedure Law in the TPL financial statements, which arise from the deferred tax effects in the TFRS financial statements.

NOTE 24 - EARNINGS PER SHARE

The weighted average number of shares and earnings per share is as follows:

	1 January-30 June 2026	**1 April-30 June 2026**	**1 January-30 June 2025**	**1 April-30 June 2025**
Weighted average number of shares	191,012	191,012	191,012	191,012
Net gain/(loss) for the period for the equity holders of the parent	3,153,018	1,368,420	3,018,030	1,379,923
Earnings/(loss) per share for equity holder of the parent	**16,51**	**7,16**	**15,80**	**7,22**

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 25 - FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES

Financial Risk Factors

Foreign currency risk management

Foreign currency risk

Transactions in foreign currencies expose the Company to foreign currency risk. Exchange rate exposures are managed within approved policy parameters utilising forward foreign exchange contracts. The carrying amounts of the Group's foreign currency denominated monetary assets and monetary liabilities at the reporting date are as follows:

30 June 2026	TRY Equivalents (Functional currency)	USD	EUR	GBP
Trade receivables	1,168,613	17,890	5,363	830
2a. Monetary financial assets	379,043	3,980	3,464	160
2b. Non monetary financial assets	48,864	249	695	3
3. Other	84,634	27	67	1,299
4. Current Assets	**1,680,974**	**22,146**	**9,589**	**2,292**
5. Trade receivables	-	-	-	-
6a. Monetary financial assets	-	-	-	-
6b. Non monetary financial assets	533,177	5,514	5,207	-
7. Other	2,234,029	27,124	18,293	-
8. Non-current assets	**2,767,206**	**32,638**	**23,500**	**-**
9. Total assets	**4,448,180**	**54,784**	**33,089**	**2,292**
10. Trade Payables	(422,474)	(7,979)	(959)	(1)
11a. Financial liabilities (leasing)	(2,030,421)	-	(38,241)	-
11b. Financial liabilities (leasing)	(52,101)	-	(981)	-
11c. Lease Liabilities	(45,233)	-	(852)	-
12a. Other monetary liabilities	(432,316)	(5,104)	(3,628)	(34)
13. CURRENT LIABILITIES	**(2,982,545)**	**(13,083)**	**(44,661)**	**(35)**
14.Trade Payables	-	-	-	-
15a. Financial liabilities (leasing)	(1,872,150)	-	(35,260)	-
15b. Financial liabilities (leasing)	-	-	-	-
15c. Lease Liabilities	(273,703)	-	(5,155)	-
16a. Other monetary liabilities	-	-	-	-
16b. Other non-monetary liabilities	(174,582)	(3,750)	-	-
17. LONG TERM LIABILITIES	**(2,320,435)**	**(3,750)**	**(40,415)**	**-**
18. TOTAL LIABILITIES	**(5,302,980)**	**(16,833)**	**(85,076)**	**(35)**
19. Net assets / liability position of off-balance sheet derivatives (19a-19b)	-	-	-	-
19a. Off balance sheet foreign currency derivative assets	-	-	-	-
19b. Off balance sheet foreign currency derivative liabilities	-	-	-	-
20. NET FOREIGN CURRENCY ASSET LIABILITY (9+8+19)	**(854,800)**	**37,951**	**(51,987)**	**2,257**
21. MONETARY ITEMS NET FOREIGN CURRENCY ASSET/LIABILITY POSITION (1+2a+10+11a+11b+12a+14+15+16a)	**(3,580,742)**	**8,787**	**(76,249)**	**955**

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 25 - FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES (Continued)

31 December 2025	TRY Equivalents (Functional currency)	USD	EUR	GBP
1. Trade receivables	1,679,162	25,387	5,836	750
2a. Monetary financial assets	795,373	8,314	6,145	157
2b. Non monetary financial assets	18,438	79	240	3
3. Other	2,355	20	21	1
4. Current Assets	**2,495,328**	**33,800**	**12,242**	**910**
5. Trade receivables	-	-	-	-
6a. Monetary financial assets	-	-	-	-
6b.Non monetary financial assets	917,783	13,134	4,289	-
7. Other	1,983,683	18,243	16,518	1,197
8. Non-current assets	**2,901,466**	**31,377**	**20,807**	**1,197**
9. Total assets	**5,396,794**	**65,177**	**33,049**	**2,108**
10. Trade payables	(1,221,768)	(22,698)	(1,280)	(1)
11a. Financial liabilities (loans)	(414,524)	-	(6,977)	-
11b. Financial liabilities (leasing)	(13,938)	-	(235)	-
11c. Lease liabilities	(71,355)	-	(1,201)	-
12a. Other monetary liabilities	(348,616)	(3,506)	(2,883)	(5)
13. Current liabilities	**(2,070,200)**	**(26,204)**	**(12,575)**	**(6)**
14. Trade payables	-	-	-	-
15a. Financial liabilities (loans)	(3,861,612)	-	(64,996)	-
15b. Financial liabilities (leasing)	(51,193)	-	(862)	-
15c. Lease liabilities	(53,829)	-	(906)	-
16a. Other monetary liabilities	(908,129)	(17,992)	-	-
16b. Other non-monetary liabilities	-	-	-	-
17. Non-current liabilities	**(4,874,763)**	**(17,992)**	**(66,764)**	**-**
18.Total liabilities	**(6,944,963)**	**(44,196)**	**(79,339)**	**(6)**
19. Net assets / liability position of off-balance sheet derivatives (19a-19b)	**-**	**-**	**-**	**-**
19a. Off balance sheet foreign currency derivative assets	**-**	**-**	**-**	**-**
19b. Off balance sheet foreign currency derivative liabilities	**-**	**-**	**-**	**-**
20. Net foreign currency asset liability position (9-18+19)	**(1,548,169)**	**20,981**	**(46,290)**	**2,102**
21. . Monetary Items Net Foreign Currency Asset/Liability Position (1+2a+10+11+12a+14+15+16a)	**(4,470,428)**	**(10,495)**	**(67,358)**	**901**

<u>Foreign currency sensitivity</u>

The Group is exposed to foreign exchange risk arising primarily from USD and EUR.

The following table details the Group's sensitivity to a 20% increase and decrease against the relevant foreign currencies. 20% is the sensitivity rate used when reporting foreign currency risk internally to key management personnel and represents management's assessment of the possible change in foreign exchange rates. The sensitivity analysis includes only outstanding foreign currency denominated monetary items and adjusts their translation at the period end for a 20% change in foreign currency rates. The sensitivity analysis includes external loans as well as loans to foreign operations within the Group where the denomination of the loan is in a currency other than the currency of the lender or the borrower. A positive number below indicates an increase in profit before tax.

(Amounts expressed in thousands Turkish Lira ("TRY") unless otherwise stated.)

NOTE 25 - FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES (Continued)

	30 June 2026	
	Profit / (Loss)	
	Valuation of foreign currency	Devaluation of foreign currency
In the case of US dollar gaining 20% value against TRY		
1- USD net asset/liability	353,363	(353,363)
2- Portion hedged against USD risk (-)	-	-
3- USD net effect (1 +2)	**353,363**	**(353,363)**
In the case of EUR gaining 20% value against TRY		
4 -EUR net asset/liability	(552,056)	552,056
5 - Portion hedged against EUR risk (-)	-	-
6- EUR net effect (4+5)	**(552,056)**	**552,056**
In the case of GBP gaining 20% value against TRY		
7- Other currency net asset/liabilitit	27,733	(27,733)
8 - Portion hedged against other currency risk (-)	-	-
9- Other currency net effect (7+8)	**27,733**	**(27,733)**
TOTAL (3+6)	**(170,960)**	**170,960**

	31 December 2025	
	Profit / (Loss)	
	Valuation of foreign currency	Devaluation of foreign currency
In the case of US dollar gaining 20% value against TRY		
1- USD net asset/liability	211,801	(211,801)
2- Portion hedged against USD risk (-)	-	-
3- USD net effect (1 +2)	**211,801**	**(211,801)**
In the case of EUR gaining 20% value against TRY		
4 -EUR net asset/liability	(550,050)	550,050
5 - Portion hedged against EUR risk (-)	-	-
6- EUR net effect (4+5)	**(550,050)**	**550,050**
In the case of GBP gaining 20% value against TRY		
7- Other currency net asset/liabilitit	28,616	(28,616)
8 - Portion hedged against other currency risk (-)	-	-
9- Other currency net effect (7+8)	**28,616**	**(28,616)**
TOTAL (3+6)	**(309,633)**	**309,633**

NOTE 26 – EVENTS AFTER THE REPORTING PERIOD

None.